Latest News

• share
• favorite_border

Ana Fernandez-Sesma, PhD, has been appointed Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. Dr. Fernandez-Sesma will direct all educational and research functions of the Department, while cultivating an academic culture that advances insights into virology, vaccinology, immunology, and microbiology, and encourages innovative approaches to teaching and mentoring.

• share
• favorite_border

The Mount Sinai Health System’s esophagectomy program has received a three-star (excellent performance) overall composite score from the Society of Thoracic Surgeons (STS).

• share
• favorite_border

The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

• share
• favorite_border

Mount Sinai Health System has been named one of “America’s Most Innovative Companies 2023” by Fortune magazine.

• share
• favorite_border

Reproductive health experts from the Mount Sinai Health System are presenting research at the 70th Annual Meeting of the Society for Reproductive Investigation (SRI) in Brisbane, Australia from March 21-25.

• share
• favorite_border

In an effort to expand equitable health care throughout New York City, the Digital and Technology Partners (DTP) department at Mount Sinai Health System is collaborating with The New York Public Library (NYPL) to support access to health services through electronic information or technologies—better known as telehealth—and digital literacy skills.

• share
• favorite_border

Two top cancer experts have been named to lead Mount Sinai’s new Tisch Cancer Hospital, which is under development and due to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.

• share
• favorite_border

Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-center study further demonstrated that the schizophrenia risk conferred by these rare damaging variants is conserved across ethnicities. The study may also point to new therapeutics. The findings were published in the March 13 online issue of Nature Genetics.

• share
• favorite_border

• share
• favorite_border

The Mount Sinai Health System joined an international task force of 52 hearing experts to develop guidelines and guidance to improve the standard of hearing care for adults. The new Living Guidelines, released today on World Hearing Day, detail best practices for treating and diagnosing hearing loss. One of the nine recommendations includes assessing adults for cochlear implants.

• share
• favorite_border

Mount Sinai Health System and Memorial Sloan Kettering Cancer Center researchers have developed a new drug delivery approach that uses nanoparticles to enable more effective and targeted delivery of anti-cancer drugs to treat brain tumors in children.

• share
• favorite_border

Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States. Although highly treatable and preventable, about 140,000 Americans are diagnosed and more than 50,000 people die each year, according to the Centers for Disease Control and Prevention (CDC). The United States Preventative Task Force recommends starting age of screening from 50 to 45.

• share
• favorite_border

To celebrate unsung heroes, Mount Sinai Health System has launched a video series that captures the pride and dedication of individuals—many in unassuming roles—who chose a long-term career in health care.

• share
• favorite_border

The American Academy of Microbiology has elected Florian Krammer, PhD, Mount Sinai Professor in Vaccinology, and Gustavo Palacios, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, along with 63 peers to its Class of 2023 fellows. Fellows of the American Academy of Microbiology, an honorary leadership group and a think tank within the American Society for Microbiology (ASM), are elected annually through a highly selective peer-review process based on their records of scientific achievement and original contributions that have advanced microbiology.

• share
• favorite_border

Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Genitourinary Cancers Symposium in February.

• share
• favorite_border

• share
• favorite_border

Researchers Develop One of the First Screening Methods Using Wearables During Sleep to Predict and Detect the Onset of Parkinson’s Disease

• share
• favorite_border

• share
• favorite_border

The Arnhold Institute for Global Health at Mount Sinai has received $8 million from the Arnhold Foundation, enabling doctors, researchers, and students to advance its already-strong base of clinical education programs, training, research, and care services to address the world’s leading health issues and improve global health systems.

• share
• favorite_border

High-risk pregnancy specialists available for interview about new studies and other maternal-fetal health topics

• share
• favorite_border

Notalgia paresthetica is a common and underdiagnosed condition characterized by a persistent itch in the upper back. To date, there are no FDA-approved treatments specifically targeting this disorder. But a new study, published in the NEJM, suggests that patients with the disorder could potentially get relief with oral difelikefalin.

• share
• favorite_border

Medical students at the Icahn School of Medicine at Mount Sinai are challenging a traditional model of medical education they say omits a critical ingredient: preparing students for the experience of segregation within health care.

• share
• favorite_border

• share
• favorite_border

Seeking to address racism and bias against Asian Americans and Pacific Islanders (AAPI), as well as the under-representation of AAPI in leadership roles in medicine, Mount Sinai announced today the launch of the Center for Asian Equity and Professional Development (CAEPD). This innovative undertaking represents one of the first of its kind nationwide by an academic medical center.

• share
• favorite_border

The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai is delighted to announce a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology.

• share
• favorite_border

Doctors warn about lack of knowledge of administering CPR, especially in high-risk groups, and the rise of stress-related heart issues

• share
• favorite_border

The Dubin Breast Center of The Tisch Cancer Institute at the Mount Sinai Health System celebrated its 12th anniversary with its annual gala on Monday, December 12.

• share
• favorite_border

Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer patients. Results from a phase 2 clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) in December.

• share
• favorite_border

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

• share
• favorite_border

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped